Top News
Latest News
PARTNERSHIPS
7 Apr 2026
Insilico Does the Math, Lilly Writes the Check
Eli Lilly pays $115M upfront to license AI-designed oral drug candidates from Insilico Medicine in a deal worth up to $2.75B
INVESTMENT
6 Apr 2026
Meet the Startup Trying to Out-Ozempic Ozempic
Ambrosia Biosciences closes an oversubscribed $100M Series B to launch US trials for a novel oral GLP-1 drug
PARTNERSHIPS
31 Mar 2026
The Shot Is So Last Year. Lilly Wants You to Pop a Pill
Eli Lilly and Nimbus Therapeutics team up in a deal worth up to $1.3B to develop a new oral obesity drug
REGULATORY
26 Mar 2026
Wegovy Turns Up the Dial and Takes Aim at Lilly
The FDA approved Novo Nordisk's 7.2 mg Wegovy HD in 54 days, with trial data showing 20.7% average weight loss
INVESTMENT
23 Mar 2026
Oral Obesity Pill Push Draws $287M Bet
Corxel secures $287M to advance its oral GLP-1 pill CX11 through US and global trials as demand for needle-free options rises
PARTNERSHIPS
17 Mar 2026
Why Novo Nordisk Is Putting $2 Billion Into a Pill
Novo Nordisk and Vivtex join forces in a $2.1B deal to develop next-generation oral biologics for obesity and diabetes
topics on the agenda
AI-DISCOVERED PEPTIDES: A NON-PHARMACEUTICAL BREAKTHROUGH FOR WEIGHT MANAGEMENT
DAY 1: undefined
09:40 - 10:05
GLOBAL PREVENTION OF DIABETES
DAY 1: undefined
10:10 - 10:35
PANEL DISCUSSION ON THE SILENT EPIDEMIC OF METABOLIC SYNDROME
DAY 1: undefined
11:00 - 11:30
SUBSCRIBE FOR UPDATES
By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.